Publication List

1. Accrombessi, G., et al. (2022). “An ecological animal model of subthreshold depression in adolescence: behavioral and resting state 18F-FDG PET imaging characterization.” Translational Psychiatry 12(1): 356.

2. Aghakhanyan, G., et al. (2022). “Interplay of tau and functional network connectivity in progressive supranuclear palsy: A [18F] PI-2620 PET/MRI study.” European Journal of Nuclear Medicine and Molecular Imaging 50(1): 103-114.

3. Ahenkorah, S., et al. (2022). “3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals.” Theranostics 12(13): 5971.

4. Akkermans, J., et al. (2022). “Identification of pre-synaptic density networks using [11C] UCB-J PET imaging and ICA in mice.” NeuroImage 264: 119771.

5. Alberts, T., et al. (2022). “Olfactory Bulb D2/D3 Receptor Availability after Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease.” Toxins 14(2): 94.

6. Alexander, K. A., et al. (2022). “Lymphocytes Are Not Required for Neurogenic Heterotopic Ossification Development after Spinal Cord Injury.” Neurotrauma Reports 3(1): 87-96.

7. Aljohani, F. S., et al. (2022). “Novel 1, 2, 3-triazole-sulphadiazine-ZnO hybrids as potent antimicrobial agents against carbapenem resistant bacteria.” Antibiotics 11(7): 916.

8. Alluri, S., et al. (2022). “Preclinical evaluation of new C-11 labeled benzo-1, 4-dioxane PET radiotracers for brain α2C adrenergic receptors.” European Journal of Medicinal Chemistry 243: 114764.

9. Almeida, S. F., et al. (2022). “Osteosarcoma‐Derived Exosomes as Potential PET Imaging Nanocarriers for Lung Metastasis.” Small 18(49): 2203999.

10. Amboni, M., et al. (2022). “Machine learning can predict mild cognitive impairment in Parkinson’s disease.” Frontiers in Neurology 13: 1010147.

11. Ambur Sankaranarayanan, R., et al. (2022). “PARP targeted Auger emitter therapy with [125I] PARPi-01 for triple-negative breast cancer.” EJNMMI research 12(1): 1-12.

12. Andersen, K. B., et al. (2022). “Healthy brain aging assessed with [18F] FDG and [11C] UCB-J PET.” Nuclear Medicine and Biology 112: 52-58.

13. Antons, M., et al. (2022). “Longitudinal [18] UCB-H/[18F] FDG imaging depicts complex patterns of structural and functional neuroplasticity following bilateral vestibular loss in the rat.” Scientific Reports 12(1): 1-12.

14. Antunes, G. L., et al. (2022). “Airway inflammation induces anxiety-like behavior through neuroinflammatory, neurochemical, and neurometabolic changes in an allergic asthma model.” Metabolic Brain Disease 37(4): 911-926.

15. Archer, S. L., et al. (2022). “SARS-CoV-2 mitochondriopathy in COVID-19 pneumonia exacerbates hypoxemia.” Redox Biology 58: 102508.

16. Ardanaz, C. G., et al. (2022). “GLUT1 ablation in astrocytes paradoxically improves central and peripheral glucose metabolism via enhanced insulin-stimulated ATP release.” bioRxiv: 2022.2010. 2006.511112.

17. Ardipradja, K. S., et al. (2022). “18F Site-Specific Labelling of a Single-Chain Antibody against Activated Platelets for the Detection of Acute Thrombosis in Positron Emission Tomography.” International Journal of Molecular Sciences 23(13): 6886.

18. Arisawa, T., et al. (2022). “Synthesis of [18F] fluorine-labeled K-2 derivatives as radiotracers for AMPA receptors.” Nuclear Medicine and Biology 110: 47-58.

19. Astley, C., et al. (2022). “In‐depth cardiovascular and pulmonary assessments in children with multisystem inflammatory syndrome after SARS‐CoV‐2 infection: A case series study.” Physiological Reports 10(5): e15201.

20. Avendaño‐Estrada, A., et al. (2022). “Comparative analysis of striatal [18F] FDOPA uptake in a partial lesion model of Parkinson’s disease in rats: ratio method versus graphical model.” Synapse 76(5-6): e22231.

21. Bachmann, D., et al. (2022). “Lifestyle affects amyloid burden and cognition differently in men and women.” Annals of Neurology.

22. Backhaus, P., et al. (2022). “Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga] Ga-OncoFAP-DOTAGA.” European Journal of Nuclear Medicine and Molecular Imaging 49(6): 1822-1832.

23. Bai, P., et al. (2022). “Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging.” Bioorganic Chemistry 123: 105779.

24. Bai, P., et al. (2022). “Development of a potential PET probe for HDAC6 imaging in Alzheimer’s disease.” Acta Pharmaceutica Sinica B.

25. Bai, P., et al. (2022). “A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain.” Chemical Communications 58(69): 9654-9657.

26. Bajorat, R., et al. (2022). “Early Post-ischemic Brain Glucose Metabolism Is Dependent on Function of TLR2: a Study Using [18F] F-FDG PET-CT in a Mouse Model of Cardiac Arrest and Cardiopulmonary Resuscitation.” Molecular Imaging and Biology 24(3): 466-478.

27. Bakrania, P., et al. (2022). “Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease.” Molecular Psychiatry 27(2): 840-848.

28. Bao, F., et al. (2022). “Mitolysosome exocytosis, a mitophagy-independent mitochondrial quality control in flunarizine-induced parkinsonism-like symptoms.” Science advances 8(15): eabk2376.

29. Barta, P., et al. (2022). “Preparation, In Vitro Affinity, and In Vivo Biodistribution of Receptor-Specific 68Ga-Labeled Peptides Targeting Vascular Endothelial Growth Factor Receptors.” Bioconjugate Chemistry 33(10): 1825-1836.

30. Bartos, L. M., et al. (2022). “18 kDa translocator protein positron emission tomography facilitates early and robust tumor detection in the immunocompetent SB28 glioblastoma mouse model.” Frontiers in Medicine: 2848.

31. Baz, A. H. C., et al. (2022). “CXCR4-directed [68Ga] Ga-PentixaFor PET/CT versus adrenal vein sampling performance: a study protocol for a randomised two-step controlled diagnoStic Trial Ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS).” BMJ Open 12(8): e060779.

32. Baz, A. H. C., et al. (2022). “Protocol: CXCR4-directed [68Ga] Ga-PentixaFor PET/CT versus adrenal vein sampling performance: a study protocol for a randomised two-step controlled diagnoStic Trial Ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS).” BMJ Open 12(8).

33. Becker, G., et al. (2022). “Exercise against cocaine sensitization in mice: a [18F] fallypride micro-PET study.” Brain Communications 4(1): fcab294.

34. Beindorff, N., et al. (2022). “Monitoring orthodontic tooth movement in rats after piezocision by bone scintigraphy.” Nuklearmedizin-NuclearMedicine 61(05): 402-409.

35. Belmar-López, C., et al. (2022). “Mesenchymal Stem Cells Delivery in Individuals with Different Pathologies: Multimodal Tracking, Safety and Future Applications.” International Journal of Molecular Sciences 23(3): 1682.

36. Benčurová, K., et al. (2022). “CAM-Xenograft Model Provides Preclinical Evidence for the Applicability of [68Ga] Ga-Pentixafor in CRC Imaging.” Cancers 14(22): 5549.

37. Bengs, S., et al. (2022). “Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice.” Journal of Nuclear Cardiology: 1-12.

38. Bertoglio, D., et al. (2022). “Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease.” Science translational medicine 14(630): eabm3682.

39. Bertoglio, D., et al. (2022). “SV2A PET imaging is a non-invasive marker for the detection of spinal damages in experimental models of spinal cord injury.” Journal of Nuclear Medicine.

40. Bertoglio, D., et al. (2022). “Longitudinal preclinical evaluation of the novel radioligand [11C] CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease.” European Journal of Nuclear Medicine and Molecular Imaging 49(4): 1166-1175.

41. Bertoglio, D., et al. (2022). “Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.” Journal of Nuclear Medicine 63(6): 942-947.

42. Bertoglio, D., et al. (2022). “Validation, kinetic modeling, and test-retest reproducibility of [18F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice.” Journal of Cerebral Blood Flow & Metabolism: 0271678X221101648.

43. Biechele, G., et al. (2022). “Glitter in the Darkness? Nonfibrillar β-Amyloid Plaque Components Significantly Impact the β-Amyloid PET Signal in Mouse Models of Alzheimer Disease.” Journal of Nuclear Medicine 63(1): 117-124.

44. Boisson, F., et al. (2022). “Performance evaluation of the IRIS XL-220 PET/CT system, a new camera dedicated to non-human primates.” EJNMMI physics 9(1): 1-14.

45. Bonaventura, J., et al. (2022). “Target deconvolution studies of (2R, 6R)-hydroxynorketamine: an elusive search.” Molecular Psychiatry: 1-13.

46. Bossart, M., et al. (2022). “Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.” Cell Metabolism 34(1): 59-74. e10.

47. Bouter, C., et al. (2022). “F-18-FDG and F-18-Florbetaben-PET for in vivo therapy monitoring of a vaccine approach against Alzheimer’s disease targeting a novel pseudo β-hairpin structure of N-truncated amyloid-β.” Nuklearmedizin-NuclearMedicine 61(02): L48.

48. Boyle, A. J., et al. (2022). “PET Imaging of Fructose Metabolism in a Rodent Model of Neuroinflammation with 6-[18F] fluoro-6-deoxy-D-fructose.” Molecules 27(23): 8529.

49. Bratanovic, I. J., et al. (2022). “A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer.” Journal of Nuclear Medicine 63(3): 424-430.

50. Breuil, L., et al. (2022). “Comparison of the Blood–Brain Barrier Transport and Vulnerability to P-Glycoprotein-Mediated Drug–Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging.” Pharmaceutics 14(8): 1658.

51. Breuil, L., et al. (2022). “Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?” Journal of Cerebral Blood Flow & Metabolism 42(1): 175-185.

52. Breuil, L., et al. (2022). “Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [11C] metoclopramide, a PET Probe for P-Glycoprotein Function at the Blood-Brain Barrier.” Pharmaceutics 14(12): 2650.

53. Bun, S., et al. (2022). “Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample.” Neuropsychopharmacology Reports 42(4): 437-448.

54. Campanholo, K., et al. (2022). “Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study.” Multiple Sclerosis and Related Disorders 57: 103331.

55. Campos-Sánchez, J. C., et al. (2022). “Ultrasonography and X-ray micro-computed tomography characterization of the effects caused by carrageenin in the muscle of gilthead seabream (Sparus aurata).” Fish & Shellfish Immunology 123: 431-441.

56. Capelli, G., et al. (2022). “18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy.” Nuclear Medicine Communications: 10.1097.

57. Castaldo, R., et al. (2022). “A Complex Radiomic Signature in Luminal Breast Cancer from a Weighted Statistical Framework: A Pilot Study.” Diagnostics 12(2): 499.

58. Ceccarini, J., et al. (2022). “Cannabinoid receptor availability modulates the magnitude of dopamine release in vivo in the human reward system: A preliminary multitracer positron emission tomography study.” Addiction Biology 27(3): e13167.

59. Chan, C. Y., et al. (2022). “Imaging PARP with [18F] rucaparib in pancreatic cancer models.” European Journal of Nuclear Medicine and Molecular Imaging: 1-11.

60. Chan, C. Y., et al. (2022). “Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F] olaparib in mouse models of glioma.” EJNMMI research 12(1): 1-10.

61. Chan, S.-C., et al. (2022). “Prospective Investigation of 18FDG-PET/MRI with Intravoxel Incoherent Motion Diffusion-Weighted Imaging to Assess Survival in Patients with Oropharyngeal or Hypopharyngeal Carcinoma.” Cancers 14(24): 6104.

62. Chen, K.-T., et al. (2022). “Individual cerebrocerebellar functional network analysis decoding symptomatologic dynamics of postoperative cerebellar mutism syndrome.” Cerebral cortex communications 3(1): tgac008.

63. Chen, M.-L. and R.-M. Wu (2022). “Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.” Journal of Biomedical Science 29(1): 60.

64. Chen, X., et al. (2022). “Cerebral amyloid angiopathy is associated with glymphatic transport reduction and time-delayed solute drainage along the neck arteries.” Nature Aging 2(3): 214-223.

65. Chen, Y.-A., et al. (2022). “Monitoring HDAC4 Expression in Alzheimer’s Disease Using.” Future Trends and Challenges of Molecular Imaging and AI Innovation: Proceedings of FASMI 2020 272: 61.

66. Chen, Z., et al. (2022). “Imaging leucine-rich repeat kinase 2 in vivo with 18F-labeled positron emission tomography ligand.” Journal of Medicinal Chemistry 66(3): 1712-1724.

67. Chen, Z., et al. (2022). “PET Imaging of Bromodomain and Extra-Terminal Domain Inhibitors for the Noninvasive Assessment of Metabolic Changes in the Liver and Brain of Early-Stage Alcoholic Liver Disease.” Molecular Pharmaceutics.

68. Cheng, G., et al. (2022). “Ultrasmall coordination polymers for alleviating ROS-mediated inflammatory and realizing neuroprotection against Parkinson’s disease.” Research 2022.

69. Cheng, M.-F., et al. (2022). “Neuroinflammation in Low-Level PM2. 5-Exposed Rats Illustrated by PET via an Improved Automated Produced [18F] FEPPA: A Feasibility Study.” Molecular Imaging 2022.

70. Cherix, A., et al. (2022). “Deletion of Crtc1 leads to hippocampal neuroenergetic impairments associated with depressive-like behavior.” Molecular Psychiatry 27(11): 4485-4501.

71. Choi, H., et al. (2022). “Quantitative Biodistribution and Pharmacokinetics Study of GMP-Grade Exosomes Labeled with 89Zr Radioisotope in Mice and Rats.” Pharmaceutics 14(6): 1118.

72. Chong, A., et al. (2022). “Pattern of F-18 FDG Uptake in Colon Cancer after Bacterial Cancer Therapy Using Engineered Salmonella Typhimurium: A Preliminary In Vivo Study.” Molecular Imaging 2022.

73. Clauß, O., et al. (2022). “Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F] BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain.” Pharmaceuticals 15(3): 324.

74. Collantes, M., et al. (2022). “Preclinical safety of negatively charged microspheres (NCMs): optimization of radiolabeling for in vivo and ex vivo biodistribution studies after topical administration on full-thickness wounds in a rat model.” European Journal of Pharmaceutics and Biopharmaceutics.

75. Convert, L., et al. (2022). “The ultra high sensitivity blood counter: a compact, MRI-compatible, radioactivity counter for pharmacokinetic studies in μl volumes.” Biomedical Physics & Engineering Express 8(3): 035022.

76. Craveiro, R. B., et al. (2022). “[68Ga] Ga-Pentixafor and Sodium [18F] Fluoride PET Can Non-Invasively Identify and Monitor the Dynamics of Orthodontic Tooth Movement in Mouse Model.” Cells 11(19): 2949.

77. Curdt, N., et al. (2022). “Search strategy analysis of Tg4-42 Alzheimer Mice in the Morris Water Maze reveals early spatial navigation deficits.” Scientific Reports 12(1): 1-14.

78. Da Pieve, C., et al. (2022). “New Fully Automated Preparation of High Apparent Molar Activity 68Ga-FAPI-46 on a Trasis AiO Platform.” Molecules 27(3): 675.

79. Dalby, S., et al. (2022). “PET/CT imaging detects intestinal inflammation in a mouse model of doxorubicin-induced mucositis.” Frontiers in Oncology 12: 1061804.

80. Damuka, N., et al. (2022). “Initial Evaluations of the Microtubule-Based PET Radiotracer,[11C] MPC-6827 in a Rodent Model of Cocaine Abuse.” Frontiers in Medicine 9.

81. Daněk, J., et al. (2022). “Sulforaphane ameliorates metabolic changes associated with status epilepticus in immature rats.” Frontiers in Cellular Neuroscience: 97.

82. Dardano, A., et al. (2022). “Brain effect of bariatric surgery in people with obesity.” International Journal of Obesity: 1-7.

83. Daruich de Souza, C., et al. (2022). “Synthesis, In Vitro Testing, and Biodistribution of Surfactant-Free Radioactive Nanoparticles for Cancer Treatment.” Nanomaterials 12(2): 187.

84. Dassanayake, P., et al. (2022). “caliPER: A software for blood-free parametric Patlak mapping using PET/MRI input function.” NeuroImage 256: 119261.

85. de Laat, B., et al. (2022). “Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F] JNJ42259152 PET study in rats.” European Journal of Nuclear Medicine and Molecular Imaging 49(2): 492-502.

86. de Oliveira, J. V., et al. (2022). “Tumor vascular heterogeneity and the impact of subtumoral nanoemulsion biodistribution.” Nanomedicine 17(27): 2073-2088.

87. de Paula Faria, D., et al. (2022). “Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study.” International Journal of Molecular Sciences 23(3): 1076.

88. DE PAULA, J. J., et al. (2022). “Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings.” PloS one.

89. de Souza, G., et al. (2022). Evaluation of MR-less in brain amyloid-β PET Centiloid quantification. Medical Imaging 2022: Biomedical Applications in Molecular, Structural, and Functional Imaging, SPIE.

90. de Souza, G. S., et al. (2022). “Amyloid-β PET classification on cognitive aging stages using the Centiloid scale.” Molecular Imaging and Biology 24(3): 394-403.

91. de Vor, L., et al. (2022). “Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm.” Elife 11: e67301.

92. Degro, C. E., et al. (2022). “Evolving acidic microenvironments during colitis provide selective analgesic targets for a pH-sensitive opioid.” Pain: 10.1097.

93. Dehghankelishadi, P., et al. (2022). “Formulation of simvastatin within high density lipoprotein enables potent tumour radiosensitisation.” Journal of Controlled Release 346: 98-109.

94. Delva, A., et al. (2022). “Synaptic damage and its clinical correlates in people with early Huntington disease: a PET study.” Neurology 98(1): e83-e94.

95. Dewulf, J., et al. (2022). “Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments.” Pharmaceutics 14(5): 939.

96. Dias, A. H., et al. (2022). “Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients.” EJNMMI research 12(1): 1-14.

97. Dias, A. H., et al. (2022). “Clinical feasibility and impact of data-driven respiratory motion compensation studied in 200 whole-body 18F-FDG PET/CT scans.” EJNMMI research 12(1): 1-11.

98. Diniz, D. M., et al. (2022). “Mapping of Brain Activity in the Analgesia Induced by Ph α 1 β and Morphine.” Frontiers in Molecular Biosciences 8: 770471.

99. Doot, R. K., et al. (2022). “[18F] NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson’s Disease.” Cells 11(19): 3081.

100. Drieu, A., et al. (2022). “Persistent neuroinflammation and behavioural deficits after single mild traumatic brain injury.” Journal of Cerebral Blood Flow & Metabolism 42(12): 2216-2229.

101. Engbjerg, J. S., et al. (2022). “The Probe for Renal Organic Cation Secretion (4-Dimethylaminostyryl)-N-Methylpyridinium (ASP+)) Shows Amplified Fluorescence by Binding to Albumin and Is Accumulated In Vivo.” Molecular Imaging 2022.

102. Eriksen, P. L., et al. (2022). “Experimental non-alcoholic fatty liver disease causes regional liver functional deficits as measured by the capacity for galactose metabolism while whole liver function is preserved.” BMC gastroenterology 22(1): 1-10.

103. Estrada, S., et al. (2022). “Preclinical evaluation of [11C] GW457427 as a tracer for neutrophil elastase.” Nuclear Medicine and Biology 106: 62-71.

104. Fan, D., et al. (2022). “Chronic hypoperfusion due to intracranial large artery stenosis is not associated with cerebral β-amyloid deposition and brain atrophy.” Chinese Medical Journal 135(05): 591-597.

105. Fan, Z., et al. (2022). “Cyanidin 3-O-β-Galactoside Alleviated Cognitive Impairment in Mice by Regulating Brain Energy Metabolism During Aging.” Journal of Agricultural and Food Chemistry 70(4): 1111-1121.

106. Faria, D. d. P., et al. (2022). “Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study.” International Journal of Molecular Sciences.

107. Fedorova, T. D., et al. (2022). “Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up.” Parkinsonism & Related Disorders 101: 99-104.

108. Feletto, L., et al. (2022). “Influence of the use of autogenous bone particles to close the access window after maxillary sinus floor augmentation: a micro‐computed tomography and positron emission tomography study in rabbits.” Oral and Maxillofacial Surgery: 1-7.

109. Ferraro, D. A., et al. (2022). “Hot needles can confirm accurate lesion sampling intraoperatively using [18F] PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer.” European Journal of Nuclear Medicine and Molecular Imaging 49(5): 1721-1730.

110. Finze, A., et al. (2022). “Regional Associations of Cortical Superficial Siderosis and β-Amyloid-Positron-Emission-Tomography Positivity in Patients With Cerebral Amyloid Angiopathy.” Frontiers in aging neuroscience 13: 786143.

111. Fragoso Costa, P., et al. (2022). “Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system.” BMC cancer 22(1): 1-18.

112. Freyssin, A., et al. (2022). “Trans ε-Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer’s Mouse Model.” Frontiers in Neuroscience 15: 803927.

113. Frisch, K., et al. (2022). “N-(4-[18F] fluorobenzyl) cholylglycine, a potential tracer for positron emission tomography of enterohepatic circulation and drug-induced inhibition of ileal bile acid transport. A proof-of-concept PET/CT study in pigs.” Nuclear Medicine and Biology 114: 49-57.

114. Gan, Y.-L., et al. (2022). “FKBP51 mediates resilience to inflammation-induced anxiety through regulation of glutamic acid decarboxylase 65 expression in mouse hippocampus.” Journal of Neuroinflammation 19(1): 1-21.

115. Garcia-Varela, L., et al. (2022). “Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F] MC225 and PET.” Journal of Controlled Release 347: 500-507.

116. Garnier‐Crussard, A., et al. (2022). “White matter hyperintensity topography in Alzheimer’s disease and links to cognition.” Alzheimer’s & Dementia 18(3): 422-433.

117. Ghazanfari, N., et al. (2022). “Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D2 and Histamine H3 Receptors: A PET Study in Healthy Rats.” Molecular Pharmaceutics.

118. Ghazanfari, N., et al. (2022). “Pharmacokinetic Modeling of [11C] GSK-189254, PET Tracer Targeting H3 Receptors, in Rat Brain.” Molecular Pharmaceutics 19(3): 918-928.

119. Giacobbo, B. L., et al. (2022). “The aged striatum: evidence of molecular and structural changes using a longitudinal multimodal approach in mice.” Frontiers in aging neuroscience: 9.

120. Girard, A., et al. (2022). “Impact of point-spread function reconstruction on dynamic and static 18F-DOPA PET/CT quantitative parameters in glioma.” Quantitative Imaging in Medicine and Surgery 12(2): 1397.

121. Giridharan, V. V., et al. (2022). “A crosstalk between gut and brain in sepsis-induced cognitive decline.” Journal of Neuroinflammation 19(1): 1-16.

122. Glatting, F. M., et al. (2022). “Repetitive early 68Ga-FAPI PET acquisition comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: methodologic and diagnostic implications for malignant, inflammatory/reactive, and degenerative lesions.” Journal of Nuclear Medicine 63(12): 1844-1851.

123. Glemser, P., et al. (2022). “Hybrid imaging with [68Ga] PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.” Cancer Imaging 22(1): 1-14.

124. Glorie, D., et al. (2022). “Quantification of Metabotropic Glutamate Receptor 5 Availability With Both [11C] ABP688 and [18F] FPEB Positron Emission Tomography in the Sapap3 Knockout Mouse Model for Obsessive-Compulsive–like Behavior.” Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 7(6): 607-615.

125. Goldstein, D. S. and C. Holmes (2022). “Is 18F-DOPA a valid cardiac sympathetic neuroimaging agent?” Clinical Autonomic Research 32(6): 445-453.

126. Gonzalez, J. P., et al. (2022). “Propuesta metodológica para la creación de una base de datos de pacientes normales en protocolo cerebral PET/MR FDG.” Revista Brasileira de Física Médica 16: 682-682.

127. González-Mancebo, D., et al. (2022). “Neodymium doped lanthanide fluoride nanoparticles as contrast agents for luminescent bioimaging and X-ray computed tomography.” Boletín de la Sociedad Española de Cerámica y Vidrio 61: S40-S49.

128. Graziani, F., et al. (2022). “Coronary Microvascular Dysfunction Is Associated With a Worse Cardiac Phenotype in Patients With Fabry Disease.” Cardiovascular Imaging.

129. Griebsch, N.-I., et al. (2022). “Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity.” Brain Sciences 12(11): 1437.

130. Guenther, T., et al. (2022). “Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability.” Journal of Nuclear Medicine.

131. Gündel, D., et al. (2022). “Structure-Based Design, Optimization, and Development of [18F] LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET.” Journal of Medicinal Chemistry.

132. Gündel, D., et al. (2022). “Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F] FLUDA by Positron Emission Tomography.” Pharmaceuticals 15(5): 516.

133. Günther, T., et al. (2022). “Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability.” Journal of Nuclear Medicine 63(9): 1364-1370.

134. Guo, J., et al. (2022). “Microglia Loss and Astrocyte Activation Cause Dynamic Changes in Hippocampal [18F] DPA-714 Uptake in Mouse Models of Depression.” Frontiers in Cellular Neuroscience 16.

135. Haider, A., et al. (2022). “Role of sex hormones in modulating myocardial perfusion and coronary flow reserve.” European Journal of Nuclear Medicine and Molecular Imaging 49(7): 2209-2218.

136. Haider, A., et al. (2022). “Assessment of cholesterol homeostasis in the living human brain.” Science translational medicine 14(665): eadc9967.

137. Haj-Hosseini, N., et al. (2022). “Early Detection of Oral Potentially Malignant Disorders: A Review on Prospective Screening Methods with Regard to Global Challenges.” Journal of Maxillofacial and Oral Surgery: 1-10.

138. Hamilton, J., et al. (2022). “Unpredictable chronic mild stress differentially impacts resting brain glucose metabolism in fatty acid-binding protein 7 deficient mice.” Psychiatry Research: Neuroimaging 323: 111486.

139. Handschuh, P. A., et al. (2022). “Effect of MAOA DNA methylation on human in vivo protein expression measured by [11C] harmine PET in healthy and depressed individuals.” medRxiv.

140. Handschuh, P. A., et al. (2022). “Effects of gender-affirming hormone therapy on gray matter density, microstructure and monoamine oxidase A levels in transgender subjects.” medRxiv.

141. Hanna, C., et al. (2022). “Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET.” Journal of Personalized Medicine 12(6): 860.

142. Hanna, C., et al. (2022). “Exercise Modulates Brain Glucose Utilization Response to Acute Cocaine.” Journal of Personalized Medicine 12(12): 1976.

143. Haskali, M. B., et al. (2022). “Effective Preparation of [18F] Flumazenil Using Copper-Mediated Late-Stage Radiofluorination of a Stannyl Precursor.” Molecules 27(18): 5931.

144. He, Y., et al. (2022). “Discovery, synthesis and evaluation of novel reversible monoacylglycerol lipase radioligands bearing a morpholine-3-one scaffold.” Nuclear Medicine and Biology 108: 24-32.

145. He, Y., et al. (2022). “Multi-parameter optimization: Development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain.” European Journal of Medicinal Chemistry 243: 114750.

146. He, Y., et al. (2022). “Development of High Brain-Penetrant and Reversible Monoacylglycerol Lipase PET Tracers for Neuroimaging.” Journal of Medicinal Chemistry 65(3): 2191-2207.

147. He, Y., et al. (2022). “Design, synthesis, and preliminary evaluation of [18F]-aryl flurosulfates PET radiotracers via SuFEx methods for β-amyloid plaques in Alzheimer’s disease.” Bioorganic & Medicinal Chemistry 75: 117087.

148. He, Z., et al. (2022). “SOX2 modulated astrocytic process plasticity is involved in arsenic-induced metabolic disorders.” Journal of Hazardous Materials 435: 128942.

149. Henriksen, A. C., et al. (2022). “Non-invasive quantification of cerebral glucose metabolism using Gjedde-Patlak plot and image-derived input function from the aorta.” NeuroImage 253: 119079.

150. Hermanns, N., et al. (2022). “Molecular imaging of the brain–heart axis provides insights into cardiac dysfunction after cerebral ischemia.” Basic Research in Cardiology 117(1): 52.

151. Hernandez Vargas, S., et al. (2022). “High-contrast detection of somatostatin receptor subtype-2 for fluorescence-guided surgery.” Molecular Pharmaceutics 19(11): 4241-4253.

152. Hiroyama, S., et al. (2022). “Usefulness of 18F-FPP-RGD2 PET in pathophysiological evaluation of lung fibrosis using a bleomycin-induced rat model.” European Journal of Nuclear Medicine and Molecular Imaging 49(13): 4358-4368.

153. Horimoto, Y., et al. (2022). “Effects of repetitive transcranial magnetic stimulation on cerebral glucose metabolism.” Neurological Sciences 43(3): 1879-1883.

154. Hsiao, T., et al. (2022). “Comparisons of vesicular monoamine transporter type 2 signals in Parkinson’s disease and parkinsonism secondary to carbon monoxide poisoning.” Neurotoxicology 88: 178-186.

155. Hsieh, C.-J., et al. (2022). “[18F] ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer’s disease pathology in APP/PS1 mice.” bioRxiv.

156. Hsueh, Y.-C., et al. (2022). “A Keratinocyte-Tethered Biologic Enables Location-Precise Treatment in Mouse Vitiligo.” Journal of Investigative Dermatology.

157. Hsueh, Y.-C., et al. (2022). “Keratinocyte-tethering modification for biologics enables location-precise treatment in mouse vitiligo.” bioRxiv.

158. Huang, T., et al. (2022). “Radiosynthesis and characterization of a carbon-11 PET tracer for receptor-interacting protein kinase 1.” Nuclear Medicine and Biology 110: 18-27.

159. Hugon, G., et al. (2022). “Impact of Donepezil on Brain Glucose Metabolism Assessed Using [18F] 2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimer’s Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide.” Frontiers in Neuroscience 16.

160. Hwang, J. J. and K. Pak (2022). “Development of automated segmentation of visceral adipose tissue in computed tomography.” European Journal of Radiology 157: 110559.

161. Iaccarino, L., et al. (2022). “rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data.” NeuroImage 246: 118775.

162. Iikuni, S., et al. (2022). “Development of an 111In-labeled glucagon-like peptide-1 receptor-targeting exendin-4 derivative that exhibits reduced renal uptake.” Molecular Pharmaceutics 19(3): 1019-1027.

163. Ikoma, Y., et al. (2022). “Measurement of Striatal Dopamine Release Induced by Neuropsychological Stimulation in Positron Emission Tomography With Dual Injections of [11C] Raclopride.” Frontiers in Psychiatry 13: 811136.

164. Ishibashi, K., et al. (2022). “Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain.” Clinical Nuclear Medicine: 10.1097.

165. Issa, A. S. M., et al. (2022). “A detector block-pairwise dead time correction method for improved quantitation with a dedicated BrainPET scanner.” Physics in Medicine & Biology 67(23): 235004.

166. Ito, Y., et al. (2022). “Novel approach to semi‐quantification of tracer accumulation in dopamine transporter scan.” Journal of Applied Clinical Medical Physics: e13626.

167. Ivanidze, J., et al. (2022). “Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas.” Radiology: Imaging Cancer 4(2).

168. Iwao, Y., et al. (2022). “Brain PET motion correction using 3D face-shape model: the first clinical study.” Annals of Nuclear Medicine 36(10): 904-912.

169. Jackson, L. R., et al. (2022). “Use of multimodality imaging, histology, and treatment feasibility to characterize a transgenic Rag2-null rat model of glioblastoma.” Frontiers in Oncology 12: 939260.

170. Jehl, M., et al. (2022). “Attenuation Correction Using Template PET Registration for Brain PET: A Proof-of-Concept Study.” Journal of Imaging 9(1): 2.

171. Jensen, J. B., et al. (2022). “A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals.” JCI insight 7(19).

172. Jeong, E. H., et al. (2022). “Serial changes of I-123 FP-CIT SPECT binding asymmetry in Parkinson’s disease: Analysis of the PPMI data.” Frontiers in Neurology 13: 976101.

173. Jessen, F., et al. (2022). “Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.” Alzheimer’s & Dementia.

174. Jonker, I., et al. (2022). “Antiviral treatment of neuroinflammation in schizophrenia.” as a transdiagnostic factor in the development of psychopathology and somatic symptoms: 41.

175. Kagerer, S. M., et al. (2022). “Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age.” Frontiers in aging neuroscience 14: 811146.

176. Kaneko, K.-i., et al. (2022). “[18F] DPA-714 PET imaging for the quantitative evaluation of early spatiotemporal changes of neuroinflammation in rat brain following status epilepticus.” European Journal of Nuclear Medicine and Molecular Imaging: 1-11.

177. Kang, S., et al. (2022). “MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6× Tg Alzheimer’s Disease Model Mice.” International Journal of Molecular Sciences 23(10): 5485.

178. Kang, Y., et al. (2022). “Longitudinal alterations in GABAA receptor availability over∼ one year following traumatic brain injury.” Brain Communications.

179. Kapoor, S., et al. (2022). “The effect of sulforaphane on perinatal hypoxic-ischemic brain injury in rats.” Physiological Research.

180. Kaulen, N., et al. (2022). “mGluR5 and GABAA receptor‐specific parametric PET atlas construction—PET/MR data processing pipeline, validation, and application.” Human brain mapping 43(7): 2148-2163.

181. Kersting, D., et al. (2022). “First experiences with dynamic renal [68Ga] Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate.” European Journal of Nuclear Medicine and Molecular Imaging: 1-14.

182. Kesarwani, P., et al. (2022). “Quinolinate promotes alternatively activated macrophage-induced immune tolerance in glioblastoma through the NMDA/PPARγ signaling axis.” bioRxiv: 2022.2007. 2012.499609.

183. Keshavjee, B., et al. (2022). “Stress-Induced Premature Senescence Related to Oxidative Stress in the Developmental Programming of Nonalcoholic Fatty Liver Disease in a Rat Model of Intrauterine Growth Restriction.” Antioxidants 11(9): 1695.

184. Kim, D., et al. (2022). “Application of 18F-FDG brain PET for survival prediction in a rat model of hanging-induced hypoxic brain injury.” Annals of Nuclear Medicine 36(6): 570-578.

185. Kim, D.-Y., et al. (2022). “In vivo imaging of invasive aspergillosis with 18F-fluorodeoxysorbitol positron emission tomography.” Nature Communications 13(1): 1-11.

186. Kim, H. Y., et al. (2022). “Screening of σ2 receptor ligands and in vivo evaluation of 11C-labeled 6, 7-Dimethoxy-2-[4-(4-methoxyphenyl) butan-2-yl]-1, 2, 3, 4-tetrahydroisoquinoline for potential use as a σ2 receptor brain PET tracer.” Journal of Medicinal Chemistry 65(8): 6261-6272.

187. Kim, I., et al. (2022). “Quantitative PET imaging of the CD4 pool in nonhuman primates.” European Journal of Nuclear Medicine and Molecular Imaging 50(1): 14-26.

188. Kim, J.-H., et al. (2022). “Differences in mGluR5 Availability Depending on the Level of Social Avoidance in Drug-Naïve Young Patients with Major Depressive Disorder.” Neuropsychiatric Disease and Treatment: 2041-2053.

189. Kim, S., et al. (2022). “Association between Visceral Adipose Tissue Metabolism and Alzheimer’s Disease Pathology.” Metabolites 12(3): 258.

190. Kim, S. B., et al. (2022). “Preclinical evaluation of a companion diagnostic radiopharmaceutical,[18F] PSMA-1007, in a subcutaneous prostate cancer xenograft mouse model.” Molecular Pharmaceutics 20(2): 1050-1060.

191. Kimura, T., et al. (2022). “A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model.” European Journal of Nuclear Medicine and Molecular Imaging 49(13): 4298-4311.

192. Kimura, Y., et al. (2022). “Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand,[11C] TASP457.” European Journal of Nuclear Medicine and Molecular Imaging 49(4): 1127-1135.

193. Klose, J. M., et al. (2022). “Administration routes for SSTR-/PSMA-and FAP-directed theranostic radioligands in mice.” Journal of Nuclear Medicine.

194. Kobayashi, R., et al. (2022). “Comparing medial temporal atrophy between early-onset semantic dementia and early-onset Alzheimer’s disease using voxel-based morphometry: A multicenter MRI study.” Current Alzheimer Research 19(7): 503-510.

195. Koike, T., et al. (2022). “Preclinical characterization of [18F] T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase.” European Journal of Nuclear Medicine and Molecular Imaging 49(4): 1148-1156.

196. Kojima, K., et al. (2022). “Brain 5-HT2A receptor binding and its neural network related to behavioral inhibition system.” Brain Imaging and Behavior 16(3): 1337-1348.

197. Koustoulidou, S., et al. (2022). “Synthesis and evaluation of two long-acting SSTR2 antagonists for radionuclide therapy of neuroendocrine tumors.” Pharmaceuticals 15(9): 1155.

198. Krämer, S. D., et al. (2022). “Changes of cerebral network activity after invasive stimulation of the mesencephalic locomotor region in a rat stroke model.” Experimental Neurology 347: 113884.

199. Krämer, S. D., et al. (2022). “Deep brain stimulation in the subthalamic nucleus can improve skilled Forelimb movements and retune dynamics of striatal networks in a rat stroke model.” International Journal of Molecular Sciences 23(24): 15862.

200. Kritikos, M., et al. (2022). “Assessment of Alzheimer’s Disease Imaging Biomarkers in World Trade Center Responders with Cognitive Impairment at Midlife.” World Journal of Nuclear Medicine 21(04): 267-275.

201. Kumamoto, K., et al. (2022). “Continuous bed motion in a silicon photomultiplier-based scanner provides equivalent spatial resolution and image quality in whole body PET images at similar acquisition times using the step-and-shoot method.” Journal of Nuclear Medicine Technology.

202. Kumar, M., et al. (2022). PET Imaging of Estrogen Receptors Using 18 F-Based Radioligands. Estrogen Receptors, Springer: 129-151.

203. Kuo, C. Y., et al. (2022). “Serotonin Modulates the Correlations between Obsessive-compulsive Trait and Heart Rate Variability in Normal Healthy Subjects: A SPECT Study with [123I] ADAM and Heart Rate Variability Measurement.” Clinical Psychopharmacology and Neuroscience 20(2): 271.

204. Kwan, C., et al. (2022). “Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset.” Neuroscience 480: 143-154.

205. Ladraa, S., et al. (2022). “PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption.” Science advances 8(49): eade7823.

206. Lafontaine, D., et al. (2022). “TriDFusion (3DF) image viewer.” EJNMMI physics 9(1): 1-19.

207. Laing, B. T., et al. (2022). “Anterior hypothalamic parvalbumin neurons are glutamatergic and promote escape behavior.” Current Biology.

208. Laing, B. T., et al. (2022). “Activation of the fear-responsive anterior hypothalamic area promotes avoidance and triggers compulsive grooming behavior in mice.” bioRxiv: 2022.2009. 2006.506804.

209. Le, T. M., et al. (2022). “18F-FDG PET visualizes systemic STING agonist-induced lymphocyte activation in preclinical models.” Journal of Nuclear Medicine.

210. Leal, G. N., et al. (2022). “Segmental cardiac strain assessment by two‐dimensional speckle‐tracking echocardiography in surviving MIS‐c patients: Correlations with myocardial flow reserve (MFR) by 13 N‐ammonia PET‐CT.” Microcirculation 29(3): e12750.

211. Leccisotti, L., et al. (2022). “Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.” Cardiovascular diabetology 21(1): 1-10.

212. Lee, H., et al. (2022). “Synthesis and Evaluation of a 18F-Labeled Ligand for PET Imaging of Colony-Stimulating Factor 1 Receptor.” Pharmaceuticals 15(3): 276.

213. Lee, H., et al. (2022). “Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.” Molecular Imaging and Biology: 1-11.

214. Lee, J., et al. (2022). “Development of Amyloid PET Analysis Pipeline Using Deep Learning-Based Brain MRI Segmentation—A Comparative Validation Study.” Diagnostics 12(3): 623.

215. Lee, J.-H., et al. (2022). “In vivo evaluation of six analogs of 11C-ER176 as candidate 18F-labeled radioligands for translocator protein 18 kDa (TSPO).” Journal of Nuclear Medicine.

216. Lee, J.-I., et al. (2022). “Selective neurodegeneration of the hippocampus caused by chronic cerebral hypoperfusion: F-18 FDG PET study in rats.” PloS one 17(2): e0262224.

217. Lehner, E., et al. (2022). “Microimaging of a novel intracochlear drug delivery device in combination with cochlear implants in the human inner ear.” Drug Delivery and Translational Research 12(1): 257-266.

218. Lehnert, W., et al. (2022). “Whole-body biodistribution and radiation dosimetry of [18F] PR04. MZ: a new PET radiotracer for clinical management of patients with movement disorders.” EJNMMI research 12(1): 1-9.

219. Li, E. J., et al. (2022). “Efficient delay correction for total-body PET kinetic modeling using pulse timing methods.” Journal of Nuclear Medicine 63(8): 1266-1273.

220. Li, J., et al. (2022). “Association between long‐term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using 18F‐AV‐45 and 18F‐AV‐1451 PET.” Journal of Neuroscience Research 100(2): 670-680.

221. Li, P., et al. (2022). “Early-stage differentiation between Alzheimer’s disease and frontotemporal lobe degeneration: Clinical, neuropsychology, and neuroimaging features.” Frontiers in aging neuroscience 14: 981451.

222. Li, Y., et al. (2022). “Tracer‐specific reference tissues selection improves detection of 18F‐FDG, 18F‐florbetapir, and 18F‐flortaucipir PET SUVR changes in Alzheimer’s disease.” Human brain mapping 43(7): 2121-2133.

223. Lillethorup, T. P., et al. (2022). “Spontaneous Partial Recovery of Striatal Dopaminergic Uptake Despite Nigral Cell Loss in Asymptomatic MPTP-Lesioned Female Minipigs.” Neurotoxicology.

224. Lim, M. K. Y., et al. (2022). “Inflammation, Calcification, and Bone Metabolism in the Tibiofemoral Joint as Early Biomarkers of Osteoarthritis.” BONE-D-22-00084.

225. Liu, G., et al. (2022). “Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of 18F-FDG in healthy volunteers.” European Journal of Nuclear Medicine and Molecular Imaging 49(8): 2493-2503.

226. Liu, Q., et al. (2022). “Impact Short-Lived of TOF 11C-Labeled on Brain PET Tracers With Among Suspected Patients With AD/PD: Using Hybrid PET/MRI.” Clinical Impact of Technological Innovations in Nuclear Medicine.

227. Liu, Z., et al. (2022). “Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation.” European Journal of Nuclear Medicine and Molecular Imaging 49(4): 1157-1165.

228. Loenen, A. C., et al. (2022). “Local bone metabolism during the consolidation process of spinal interbody fusion.” Journal of Bone and Mineral Metabolism 40(2): 220-228.

229. Löffler, J., et al. (2022). “Blocking studies to evaluate receptor-specific radioligand binding in the CAM model by PET and MR imaging.” Cancers 14(16): 3870.

230. Lombardi, G., et al. (2022). “PET/MR in recurrent glioblastoma patients treated with regorafenib:[18F] FET and DWI-ADC for response assessment and survival prediction.” The British Journal of Radiology 95(1129): 20211018.

231. Løndalen, A., et al. (2022). “FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?” Molecular Imaging and Biology: 1-11.

232. Lu, M., et al. (2022). “A Pilot Study of Dynamic 18F-DCFPyL PET/CT Imaging of Prostate Adenocarcinoma in High-Risk Primary Prostate Cancer Patients.” Molecular Imaging and Biology 24(3): 444-452.

233. Lu, T.-H., et al. (2022). “Striatal Dopamine Transporter Availability is Associated with Sleep Disturbance among Patients with Bipolar I Disorder: A Single-photon Emission Computed Tomography Study Using [99mTc] TRODAT-1.” Clinical Psychopharmacology and Neuroscience 20(4): 768.

234. Lue, K.-H., et al. (2022). “Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma.” Annals of Nuclear Medicine 36(3): 256-266.

235. Lue, K.-H., et al. (2022). “Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy.” Cancers 14(2): 309.

236. Mac, C.-H., et al. (2022). “Engineering a biomimetic bone scaffold that can regulate redox homeostasis and promote osteogenesis to repair large bone defects.” Biomaterials 286: 121574.

237. Marie, S., et al. (2022). “[11C] glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body.” Biomedicine & Pharmacotherapy 156: 113994.

238. Marie, S., et al. (2022). “Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats.” Pharmaceuticals 15(4): 392.

239. Martínez-Gregorio, H., et al. (2022). “Early detection of colorectal cancer somatic mutations using cfDNA liquid biopsies in a murine carcinogenesis model.” Journal of Cancer 13(13): 3404.

240. Martinez-Orengo, N., et al. (2022). “Assessing organ-level immunoreactivity in a rat model of sepsis using TSPO PET imaging.” Frontiers in Immunology 13: 1010263.

241. Matsuoka, K., et al. (2023). “Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy.” Journal of the Neurological Sciences 444: 120514.

242. Mazzoletti, A., et al. (2022). “Comparison of left ventricle mechanical dyssynchrony parameters in ischemic and non-ischemic patients using 13N-NH3 PET/CT.” Journal of Nuclear Cardiology 29(3): 1248-1253.

243. Meneghetti, M., et al. (2022). “Mapping whole brain effects of infrared neural stimulation with positron emission tomography.” bioRxiv: 2022.2012. 2024.521746.

244. Michiels, L., et al. (2022). “Simplified Edinburgh and modified Boston criteria in relation to amyloid PET for lobar intracerebral hemorrhage.” NeuroImage: Clinical 35: 103107.

245. Michiels, L., et al. (2022). “Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study.” Journal of Cerebral Blood Flow & Metabolism 42(2): 303-314.

246. Miranda, A., et al. (2022). “Spatiotemporal Kernel Reconstruction for Linear Parametric Neurotransmitter PET Kinetic Modeling in Motion Correction Brain PET of Awake Rats.” Frontiers in Neuroscience 16.

247. Miskowiak, K. W., et al. (2022). “Cerebral metabolic rate of glucose and cognitive tests in long COVID patients.” Brain Sciences 13(1): 23.

248. Miyazaki, T., et al. (2022). “Epileptic discharges initiate from brain areas with elevated accumulation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors.” Brain Communications 4(2): fcac023.

249. Mizutani, A., et al. (2022). “Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice.” Pharmaceutics 14(5): 1026.

250. Molinet-Dronda, F., et al. (2022). “Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.” Neurobiology of Disease 167: 105669.

251. Momota, Y., et al. (2022). “Case report: Non-Alzheimer’s disease tauopathy with logopenic variant primary progressive aphasia diagnosed using amyloid and tau PET.” Frontiers in Neurology 13: 1049113.

252. Monte, B., et al. (2022). “Characterization of perivascular space pathology in a rat model of cerebral small vessel disease by in vivo magnetic resonance imaging.” Journal of Cerebral Blood Flow & Metabolism: 0271678X221105668.

253. Moog, S., et al. (2022). “Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.” Endocrine-Related Cancer 29(6): 375-388.

254. Moraga-Amaro, R., et al. (2022). “A single dose of ketamine cannot prevent protracted stress-induced anhedonia and neuroinflammation in rats.” Stress 25(1): 145-155.

255. Müller, E. G., et al. (2022). “Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer’s disease.” Quantitative Imaging in Medicine and Surgery 12(1): 493.

256. Müller, M., et al. (2022). “Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.” Journal of Neuro-oncology 159(3): 519-529.

257. Munk, D. E., et al. (2022). “Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study.” Scientific Reports 12(1): 14714.

258. Murayama, C., et al. (2022). “Extrastriatal dopamine D2/3 receptor binding, functional connectivity, and autism socio-communicational deficits: a PET and fMRI study.” Molecular Psychiatry 27(4): 2106-2113.

259. Murillo, O., et al. (2022). “High value of [64Cu] CuCl2 PET as a non-invasive tool to evaluate the restoration of physiological copper excretion after VTX-801 gene therapy in a mouse model of Wilson’s disease.” Molecular Therapy-Methods & Clinical Development.

260. Nakaoka, T., et al. (2022). “Clinical evaluation of [18F] pitavastatin for quantitative analysis of hepatobiliary transporter activity.” Drug Metabolism and Pharmacokinetics 44: 100449.

261. Nakaza, M., et al. (2022). “Dual-VENC 4D flow MRI can detect abnormal blood flow in the left atrium that potentially causes thrombosis formation after left upper lobectomy.” Magnetic Resonance in Medical Sciences 21(3): 433-443.

262. Nakladal, D., et al. (2022). “Perivascular adipose tissue-derived nitric oxide compensates endothelial dysfunction in aged pre-atherosclerotic apolipoprotein E-deficient rats.” Vascular pharmacology 142: 106945.

263. Nguyen, D., et al. (2022). “Lymphatic regeneration after implantation of aligned nanofibrillar collagen scaffolds: Preliminary preclinical and clinical results.” Journal of Surgical Oncology 125(2): 113-122.

264. Nguyen, G. A., et al. (2022). “[124I] IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease.” Molecules 27(14): 4552.

265. Ni, R., et al. (2022). “Coregistered transcranial optoacoustic and magnetic resonance angiography of the human brain.” bioRxiv.

266. Ni, R., et al. (2022). “Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice.” Nature Biomedical Engineering 6(9): 1031-1044.

267. Nihashi, T., et al. (2022). “Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer’s Disease Continuum.” Journal of Alzheimer’s Disease 85(1): 223-234.

268. Nikolaus, S., et al. (2022). “The 5-HT1A receptor antagonist WAY-100635 decreases motor/exploratory behaviors and nigrostriatal and mesolimbocortical dopamine D2/3 receptor binding in adult rats.” Pharmacology Biochemistry and Behavior 215: 173363.

269. Nogami, T., et al. (2022). “Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [18F] FE-PE2I.” Frontiers in Psychiatry: 1097.

270. Øen, S. K., et al. (2022). “Diagnostic value of 18F-FACBC PET/MRI in brain metastases.” Clinical Nuclear Medicine 47(12): 1030.

271. Okazawa, H., et al. (2022). “Cerebral Oxidative Stress in Early Alzheimer’s Disease Evaluated by 64Cu-ATSM PET/MRI: A Preliminary Study.” Antioxidants 11(5): 1022.

272. Okita, K., et al. (2022). “Potential Treat-to-Target Approach for Methamphetamine Use Disorder: A Pilot Study of Adenosine 2A Receptor Antagonist With Positron Emission Tomography.” Frontiers in Pharmacology 13.

273. Ono, M., et al. (2022). “Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy.” Aging Cell: e13615.

274. Ordonez, A. A., et al. (2022). “11C-Para-aminobenzoic acid PET imaging of S. aureus and MRSA infection in preclinical models and humans.” JCI insight 7(1).

275. Oyama, K., et al. (2022). “Chemogenetic disconnection between the orbitofrontal cortex and the rostromedial caudate nucleus disrupts motivational control of goal-directed action.” bioRxiv.

276. Oyama, K., et al. (2022). “Chronic behavioral manipulation via orally delivered chemogenetic actuator in macaques.” Journal of Neuroscience 42(12): 2552-2561.

277. Oyarzabal, E. A., et al. (2022). “Chemogenetic stimulation of tonic locus coeruleus activity strengthens the default mode network.” Science advances 8(17): eabm9898.

278. Pak, K., et al. (2022). “Serotonin transporter is negatively associated with body mass index after glucose loading in humans.” Brain Imaging and Behavior 16(3): 1246-1251.

279. Pak, K., et al. (2022). “Brain glucose metabolism and ageing: A 5-year longitudinal study in a large PET cohort.” bioRxiv: 2022.2009. 2015.508088.

280. Pak, K., et al. (2022). “SLC6A3 gene polymorphisms are associated with striatal dopamine transporter changes after glucose loading.” Synapse 76(1-2): e22223.

281. Pak, K., et al. (2022). “Limited power of dopamine transporter mRNA mapping for predicting dopamine transporter availability.” Synapse 76(5-6): e22226.

282. Pak, K., et al. (2022). “Hedonic rating of sucrose is sub-regionally associated with striatal dopamine transporter in humans.” Neuroendocrinology 112(4): 338-344.

283. Palillo, M., et al. (2022). “Anesthesia with Tricaine Methanesulfonate (MS222) and Propofol and Its Use for Computed Tomography of Red Swamp Crayfish (Procambarus clarkii).” Journal of the American Association for Laboratory Animal Science 61(3): 275-282.

284. Park, D. G., et al. (2022). “Association of plasma α-synuclein with cardiac 123I-MIBG scintigraphy in early Parkinson’s disease.” Neuroscience Letters 770: 136399.

285. Park, D. G., et al. (2022). “Factors associated with motor severity in vascular parkinsonism with normal dopamine transporter imaging.” Parkinsonism & Related Disorders 94: 99-103.

286. Park, S., et al. (2022). “Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans.” Clinical and Translational Science 15(12): 2938-2946.

287. Peters, S., et al. (2022). “[68Ga] Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu] Lu-PSMA-617 treatment.” European Journal of Nuclear Medicine and Molecular Imaging 49(4): 1101-1112.

288. Piron, S., et al. (2022). “Preclinical comparative study of [18F] AlF-PSMA-11 and [18F] PSMA-1007 in varying PSMA expressing tumors.” Scientific Reports 12(1): 15744.

289. Pisaneschi, F., et al. (2022). “Imaging of innate immunity activation in vivo with a redox-tuned PET reporter.” Nature biotechnology: 1-9.

290. Pitombeira, M. S., et al. (2022). “Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study.” European Journal of Nuclear Medicine and Molecular Imaging 49(13): 4551-4566.

291. Polvoy, I., et al. (2022). “Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans.” European Journal of Nuclear Medicine and Molecular Imaging: 1-11.

292. Poojari, R., et al. (2022). “Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake.” Nanomedicine: Nanotechnology, Biology and Medicine 41: 102529.

293. Prasad, K., et al. (2022). “Impact of an adenosine A2A receptor agonist and antagonist on binding of the dopamine D2 receptor ligand [11C] raclopride in the rodent striatum.” Molecular Pharmaceutics 19(8): 2992-3001.

294. Presotto, L., et al. (2022). “Development of a new toolbox for mouse PET–CT brain image analysis fully based on CT images and validation in a PD mouse model.” Scientific Reports 12(1): 15822.

295. Prieto, E., et al. (2022). “Performance evaluation of a preclinical SPECT/CT system for multi-animal and multi-isotope quantitative experiments.” Scientific Reports 12(1): 18161.

296. Puuvuori, E., et al. (2022). “PET-CT imaging of pulmonary inflammation using [68Ga] Ga-DOTA-TATE.” EJNMMI research 12(1): 1-10.

297. Qiu, L., et al. (2022). “Radiosynthesis and evaluation of a fluorine-18 radiotracer [18 F] FS1P1 for imaging sphingosine-1-phosphate receptor 1.” Organic & Biomolecular Chemistry 20(5): 1041-1052.

298. Qiu, T., et al. (2022). “Dynamic Microglial Activation is Associated with LPS-induced Depressive-like Behavior in Mice: An [18F] DPA-714 PET Imaging Study.” Bosnian Journal of Basic Medical Sciences.

299. Raffel, D. M., et al. (2022). “Quantifying cardiac sympathetic denervation: first studies of 18F-fluorohydroxyphenethylguanidines in cardiomyopathy patients.” European Journal of Nuclear Medicine and Molecular Imaging 49(2): 619-631.

300. Raijmakers, R., et al. (2022). “No signs of neuroinflammation in women with chronic fatigue syndrome or Q fever fatigue syndrome using the TSPO ligand [11C]-PK11195.” Neurology-Neuroimmunology Neuroinflammation 9(1).

301. Ramakrishnan, N. K., et al. (2022). “Automated radiosynthesis and preclinical in vivo evaluation of [18F] Fluoroethylpuromycin as a potential radiotracer for imaging protein synthesis with PET.” Nuclear Medicine and Biology 114: 71-77.

302. Ramírez-Hernández, D., et al. (2022). “Lipomics: A Potential Carrier for the Intravenous Delivery of Lipophilic and Hydrophilic Drugs.” Pharmaceutics 14(8): 1651.

303. Rampidis, G. P., et al. (2022). “Protocol: Role of cardiac CT in the diagnostic evaluation and risk stratification of patients with myocardial infarction and non-obstructive coronary arteries (MINOCA): rationale and design of the MINOCA-GR study.” BMJ Open 12(2).

304. Rampidis, G. P., et al. (2022). “Role of cardiac CT in the diagnostic evaluation and risk stratification of patients with myocardial infarction and non-obstructive coronary arteries (MINOCA): rationale and design of the MINOCA-GR study.” BMJ Open 12(2): e054698.

305. Rapp, C., et al. (2022). “Alcohol binge drinking decreases brain glucose metabolism and functional connectivity in adolescent rats.” Metabolic Brain Disease: 1-8.

306. Raval, N. R., et al. (2022). “Evaluation of the α-synuclein PET radiotracer (d3)-[11C] MODAG-001 in pigs.” bioRxiv.

307. Raval, N. R., et al. (2022). “An in vivo pig model for testing novel PET radioligands targeting cerebral protein aggregates.” bioRxiv: 2021.2012. 2031.473908.

308. Raval, N. R., et al. (2022). “An in vivo Pig Model for Testing Novel Positron Emission Tomography Radioligands Targeting Cerebral Protein Aggregates.” Frontiers in Neuroscience 16.

309. Reincke, M., et al. (2022). “Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.” Hepatology Communications 6(11): 3223-3233.

310. Reverte, V., et al. (2022). “Integrative Cardiovascular Physiology and Pathophysiology: SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet.” American Journal of Physiology-Heart and Circulatory Physiology 322(4): H523.

311. Reverte, V., et al. (2022). “SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet.” American Journal of Physiology-Heart and Circulatory Physiology 322(4): H523-H536.

312. Richard, G., et al. (2022). “High-fructose feeding suppresses cold-stimulated brown adipose tissue glucose uptake in young men independently of changes in thermogenesis and the gut microbiome.” bioRxiv.

313. Richer, K., et al. (2022). “Chronic treatment and abstinence from methylphenidate exposure dose-dependently changes glucose metabolism in the rat brain.” Brain Research 1780: 147799.

314. Rischka, L., et al. (2022). “Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C] Me-NB1.” EJNMMI research 12(1): 1-8.

315. Rischka, L., et al. (2022). “First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-11C-Me-NB1.” Journal of Nuclear Medicine 63(6): 936-941.

316. Rissanen, E., et al. (2022). “Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis.” Neurology-Neuroimmunology Neuroinflammation 9(2).

317. Roczkowsky, A., et al. (2022). “Peroxisome injury in multiple sclerosis: protective effects of 4-phenylbutyrate in CNS-associated macrophages.” Journal of Neuroscience 42(37): 7152-7165.

318. Röhrich, M., et al. (2022). “Fibroblast activation protein–specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.” Journal of Nuclear Medicine 63(1): 127-133.

319. Rudroff, T., et al. (2022). “On the Effects of Transcranial Direct Current Stimulation on Cerebral Glucose Uptake During Walking: A Report of Three Patients With Multiple Sclerosis.” Frontiers in human neuroscience 16.

320. Rudroff, T., et al. (2022). “Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study.” Brain Sciences 12(7): 819.

321. Ruiz-Bedoya, C. A., et al. (2022). “High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis.” The Journal of clinical investigation 132(6).

322. Rullmann, M., et al. (2022). “Multicenter 18F-PI-2620 PET for in vivo Braak staging of tau pathology in Alzheimer’s disease.” Biomolecules 12(3): 458.

323. Sakarya, A. H., et al. (2022). “Vascularized lymph node transplantation successfully reverses lymphedema and maintains immunity in a rat lymphedema model.” Bioengineering & Translational Medicine: e10301.

324. Sakurai, K., et al. (2022). “Age-related increase of monoamine oxidase B in amyloid-negative cognitively unimpaired elderly subjects.” Annals of Nuclear Medicine 36(8): 777-784.

325. Samanta, S., et al. (2022). “Heparin‐Derived Theranostic Nanoprobes Overcome the Blood–Brain Barrier and Target Glioma in Murine Model.” Advanced Therapeutics: 2200001.

326. Sanaat, A., et al. (2022). “Deep‐TOF‐PET: Deep learning‐guided generation of time‐of‐flight from non‐TOF brain PET images in the image and projection domains.” Human brain mapping 43(16): 5032-5043.

327. Sandahl, T. D., et al. (2022). “The pathophysiology of Wilson’s disease visualized: A human 64Cu PET study.” Hepatology 75(6): 1461-1470.

328. Sandbhor, P., et al. (2022). “Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models.” Nanoscale 14(1): 108-126.

329. Sanders, K. J., et al. (2022). “Brown adipose tissue activation is not related to hypermetabolism in emphysematous chronic obstructive pulmonary disease patients.” Journal of cachexia, sarcopenia and muscle 13(2): 1329-1338.

330. Sardana, M., et al. (2022). “Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging.” Pharmaceuticals 15(12): 1568.

331. Sari, H., et al. (2022). “First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients.” European Journal of Nuclear Medicine and Molecular Imaging 49(6): 1997-2009.

332. Say, F. M., et al. (2022). “Effects of chronic cocaine and ethanol self‐administration on brain dopamine receptors in a rhesus monkey model of polysubstance abuse.” Addiction Biology 27(5): e13219.

333. Schrader, J. M., et al. (2022). “Emergent White Matter Degeneration in the rTg-DI Rat Model of Cerebral Amyloid Angiopathy Exhibits Unique Proteomic Changes.” The American Journal of Pathology 192(3): 426-440.

334. Schramm, G., et al. (2022). “Regional Accuracy of ZTE-Based Attenuation [18F] FDG and Correction Dynamic [18F] PE2I in Static Brain PET/MR.” Quantification in Nuclear Medicine Imaging.

335. Schuster, S., et al. (2022). “Impact of Partial Volume Correction on [18F] GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome.” Brain Sciences 12(2): 204.

336. Schweickert de Palma, E., et al. (2022). “Availability of central α4β2* nicotinic acetylcholine receptors in human obesity.” Brain Sciences 12(12): 1648.

337. Scott, N., et al. (2022). “Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.” British journal of cancer 126(4): 598-605.

338. Seiffert, A. P., et al. (2022). “Differences in Striatal Metabolism in [18F] FDG PET in Parkinson’s Disease and Atypical Parkinsonism.” Diagnostics 13(1): 6.

339. Sekine, T., et al. (2022). “4D Flow MR Imaging of the Left Atrium: What is Non-physiological Blood Flow in the Cardiac System?” Magnetic Resonance in Medical Sciences 21(2): 293-308.

340. Serrano, M. E., et al. (2022). “Imaging Synaptic Density: The Next Holy Grail of Neuroscience?” Frontiers in Neuroscience 16.

341. Shah, S., et al. (2022). “PET imaging of TSPO expression in immune cells can assess organ-level pathophysiology in high-consequence viral infections.” Proceedings of the National Academy of Sciences 119(15): e2110846119.

342. Shi, Y., et al. (2022). “Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18 kDa translocator protein (TSPO).” Nature Neuroscience 25(3): 317-329.

343. Shidahara, M., et al. (2022). “Noninvasive estimation of human radiation dosimetry of 18F-FDG by whole-body small animal PET imaging in rats.” Applied Radiation and Isotopes 181: 110071.

344. Shin, H.-J., et al. (2022). “Classification of Alzheimer’s Disease Using Dual-Phase 18F-Florbetaben Image with Rank-Based Feature Selection and Machine Learning.” Applied Sciences 12(15): 7355.

345. Shokri‐Kojori, E., et al. (2022). “Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine.” Human brain mapping 43(4): 1419-1430.

346. Shukla, P., et al. (2022). “ARID2 suppression promotes tumor progression and upregulates cytokeratin 8, 18 and β-4 integrin expression in TP53-mutated tobacco-related oral cancer and has prognostic implications.” Cancer Gene Therapy 29(12): 1908-1917.

347. Shukuri, M., et al. (2022). “Synthesis and Preclinical Evaluation of 18F-labeled Ketoprofen Methyl Esters for Cyclooxygenase-1 Imaging in Neuroinflammation.” Journal of Nuclear Medicine.

348. Skjærbæk, C., et al. (2022). “Intestinal Transit in Early Moderate Parkinson’s Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate.” Parkinson’s Disease 2022.

349. Solas, M., et al. (2022). “The Cognitive Improvement and Alleviation of Brain Hypermetabolism Caused by FFAR3 Ablation in Tg2576 Mice Is Persistent under Diet-Induced Obesity.” International Journal of Molecular Sciences 23(21): 13591.

350. Song, A. K., et al. (2022). “Amphetamine-induced dopamine release and impulsivity in Parkinson’s disease.” Brain 145(10): 3488-3499.

351. SOUZA, C. D. d., et al. (2022). “Synthesis, in vitro testing, and biodistribution of surfactant-free radioactive nanoparticles for cancer treatment.” Nanomaterials.

352. Stabin, M. G., et al. (2022). “RADAR guide: standard methods for calculating radiation doses for radiopharmaceuticals, part 2—data analysis and dosimetry.” Journal of Nuclear Medicine 63(3): 485-492.

353. Staudacher, A. H., et al. (2022). “Fc gamma receptor is not required for in vivo processing of radio-and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.” Biomedicine & Pharmacotherapy 151: 113090.

354. Stavropoulou, A. P., et al. (2022). “Bimetallic gold-platinum nanoparticles as a drug delivery system coated with a new drug to target glioblastoma.” Colloids and Surfaces B: Biointerfaces 214: 112463.

355. Stormezand, G. N., et al. (2022). “Imaging of neuroinflammation due to repetitive head injury in currently active kickboxers.” European Journal of Nuclear Medicine and Molecular Imaging: 1-11.

356. Suchacki, K. J., et al. (2022). “The effects of caloric restriction on adipose tissue and metabolic health are sex-and age-dependent.” bioRxiv.

357. Sugisawa, E., et al. (2022). “Nociceptor-derived Reg3γ prevents endotoxic death by targeting kynurenine pathway in microglia.” Cell Reports 38(10): 110462.

358. Sukprakun, C., et al. (2022). “A Novel method of seizure onset zone localization by serial Tc-99 m ECD brain perfusion SPECT clearance patterns.” Brain Imaging and Behavior: 1-11.

359. Tagai, K., et al. (2022). “An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607).” medRxiv.

360. Takahashi, M., et al. (2022). “Small nuclei identification with a hemispherical brain PET.” EJNMMI physics 9(1): 69.

361. Takahata, K., et al. (2022). “First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F-T-401.” European Journal of Nuclear Medicine and Molecular Imaging: 1-12.

362. Takamura, Y., et al. (2022). “Teratogenicity and Fetal-Transfer Assessment of the Retinoid X Receptor Agonist Bexarotene.” ACS Pharmacology & Translational Science 5(9): 811-818.

363. Talkington, A. M., et al. (2022). “A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.” Journal of Controlled Release 343: 518-527.

364. Tan, Q., et al. (2022). “Imaging Study on Acupuncture Inhibiting Inflammation and Bone Destruction in Knee Osteoarthritis Induced by Monosodium Iodoacetate in Rat Model.” Journal of Pain Research 15: 93.

365. Tanaka, A., et al. (2022). “Reproducibility of standardized uptake values including volume metrics between TOF-PET-MR and TOF-PET-CT.” Frontiers in Medicine: 455.

366. Tang, Z., et al. (2022). “Chemical Factory‐Guaranteed Enhanced Chemodynamic Therapy for Orthotopic Liver Cancer.” Advanced Science: 2201232.

367. Taubel, J. C., et al. (2022). “Design, Synthesis, and Preliminary Evaluation of [68Ga] Ga-NOTA-Insulin as a PET Probe in an Alzheimer’s Disease Mouse Model.” Bioconjugate Chemistry 33(5): 892-906.

368. Teng, Y.-H. and T.-L. Kung (2022). Super-Connectivity of Locally Twisted Cubes. International Conference on Innovative Mobile and Internet Services in Ubiquitous Computing, Springer.

369. Terada, T., et al. (2022). “Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer’s disease.” European Journal of Neurology 29(5): 1324-1334.

370. Tomadesso, C., et al. (2022). “Plasma Levels of Tissue-Type Plasminogen Activator (tPA) in Normal Aging and Alzheimer’s Disease: Links With Cognition, Brain Structure, Brain Function and Amyloid Burden.” Frontiers in aging neuroscience 14.

371. Toramatsu, C., et al. (2022). “Measurement of biological washout rates depending on tumor vascular status in 15O in-beam rat-PET.” Physics in Medicine & Biology.

372. Tram, N. K., et al. (2022). “Novel Application of 18F-NaF PET/CT Imaging for Evaluation of Active Bone Remodeling in Diabetic Patients With Charcot Neuropathy: A Proof-of-Concept Report.” Frontiers in Medicine 9.

373. Trotta, N., et al. (2022). “Comparison of PMT‐based TF64 and SiPM‐based Vereos PET/CT systems for 90Y imaging and dosimetry optimization: A quantitative study.” Medical Physics 49(12): 7567-7582.

374. Trujillo, P., et al. (2022). “Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients.” npj Parkinson’s Disease 8(1): 1-7.

375. Truong, V. A., et al. (2022). “Bi-directional gene activation and repression promote ASC differentiation and enhance bone healing in osteoporotic rats.” Molecular Therapy 30(1): 92-104.

376. Tsai, C.-J., et al. (2022). “3, 4-Methylenedioxymethamphetamine (MDMA) Model: In Vivo 4-[18F]-ADAM PET Imaging.” International Journal of Molecular Sciences 23(13): 7035.

377. Tseng, J.-R., et al. (2022). “Impact of Three-Month Androgen Deprivation Therapy on [68Ga] Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer—Results from a Pilot Prospective Study.” Cancers 14(5): 1329.

378. Uchida, Y., et al. (2022). “APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction.” Journal of Neurology, Neurosurgery & Psychiatry.

379. Ueno-Pardi, L. M., et al. (2022). “Effects of exercise training on brain metabolism and cognitive functioning in sleep apnea.” Scientific Reports 12(1): 1-12.

380. Vainio, S., et al. (2022). “Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation.” EJNMMI research 12(1): 1-11.

381. Valda, A., et al. (2022). “Estudio preclínico en primate no-humano con [18F] Fluorotimidina. dosimetría y biodistribución.” Medicina (Buenos Aires) 82(2): 231-237.

382. van Aalst, J., et al. (2022). “Regional glucose metabolic decreases with ageing are associated with microstructural white matter changes: a simultaneous PET/MR study.” European Journal of Nuclear Medicine and Molecular Imaging 49(2): 664-680.

383. van der Weijden, C. W., et al. (2022). “Quantitative assessment of myelin density using [11C] MeDAS PET in patients with multiple sclerosis: a first-in-human study.” European Journal of Nuclear Medicine and Molecular Imaging: 1-16.

384. van der Weijden, C. W., et al. (2022). “Diffusion-derived parameters in lesions, peri-lesion, and normal-appearing white matter in multiple sclerosis using tensor, kurtosis, and fixel-based analysis.” Journal of Cerebral Blood Flow & Metabolism: 0271678X221107953.

385. Van Der Wildt, B., et al. (2022). “Discovery of a CSF-1R inhibitor and PET tracer for imaging of microglia and macrophages in the brain.” Nuclear Medicine and Biology 114: 99-107.

386. van Dijken, B. R., et al. (2022). “Ventricle contact may be associated with higher 11C methionine PET uptake in glioblastoma.” Neuroradiology 64(2): 247-252.

387. van Hooijdonk, C. F., et al. (2022). “The Relationships between Dopaminergic, Glutamatergic, and Cognitive Functioning in 22q11. 2 Deletion Syndrome: A Cross-Sectional, Multimodal 1H-MRS and 18F-Fallypride PET Study.” Genes 13(9): 1672.

388. Vehof, V., et al. (2022). “Hybrid CMR-and FDG-PET-Imaging Gives New Insights Into the Relationship of Myocardial Metabolic Activity and Fibrosis in Patients With Becker Muscular Dystrophy.” Frontiers in Cardiovascular Medicine 9.

389. Velikyan, I., et al. (2022). “Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences.” Pharmaceuticals 16(1): 61.

390. Victorio, C. B. L., et al. (2022). “Preclinical evaluation of [18F] FDG-PET as a biomarker of lymphoid tissue disease and inflammation in Zika virus infection.” European Journal of Nuclear Medicine and Molecular Imaging 49(13): 4516-4528.

391. Villemagne, V. L., et al. (2022). “First-in-human evaluation of 18F-SMBT-1, a novel 18F-labeled MAO-B PET tracer for imaging reactive astrogliosis.” Journal of Nuclear Medicine.

392. Viswanath, V., et al. (2022). “Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners.” European Journal of Nuclear Medicine and Molecular Imaging: 1-11.

393. Von Rohr, K., et al. (2022). “Can Radiomics Provide Additional Information in [18F] FET-Negative Gliomas?” Cancers 14(19): 4860.

394. Vrist, M. H., et al. (2022). “Bone Turnover, Mineralization, and Volume Estimated by 18F-Sodium Fluoride PET/CT and Biomarkers in Chronic Kidney Disease: Mineral and Bone Disorder Compared with Bone Biopsy.” American Journal of Nephrology: 1-13.

395. Wagatsuma, K., et al. (2022). “Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [18F] FDG and [11C] PiB.” Medical Physics.

396. Wakabayashi, Y., et al. (2022). “First-in-human evaluation of 18F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B.” Journal of Nuclear Medicine.

397. Wang, C., et al. (2022). “Association between cigarette smoking and Parkinson’s disease: a neuroimaging study.” Therapeutic advances in neurological disorders 15: 17562864221092566.

398. Wang, H., et al. (2022). “Evaluation of N-(6-[18F] Fluoropyridin-3-yl) glycine PET renography to detect renal function progression in a rat model of diabetic nephropathy.” Nuclear Medicine and Biology 112: 59-65.

399. Wang, L., et al. (2022). “Amyloid Beta Peptides Inhibit Glucose Transport at the Blood-brain Barrier by Disrupting Insulin-Akt Pathway in Alzheimer’s Disease.” bioRxiv: 2022.2011. 2021.517280.

400. Wang, L., et al. (2022). “Interferometrical single-molecule localization based on dynamic PSF engineering.” Optics Letters 47(7): 1770-1773.

401. Warashina, S., et al. (2022). “64Cu-labeling of small extracellular vesicle surfaces via a cross-bridged macrocyclic chelator for pharmacokinetic study by positron emission tomography imaging.” International Journal of Pharmaceutics: 121968.

402. Watanabe, H., et al. (2022). “Characterization of Radioiodinated Diaryl Oxadiazole Derivatives as SPECT Probes for Detection of Myelin in Multiple Sclerosis.” ACS Chemical Neuroscience 13(3): 363-369.

403. Wenzel, B., et al. (2022). “Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A).” Pharmaceuticals 15(10): 1272.

404. Wetherill, R. R., et al. (2022). “Using 18F-NOS PET Imaging to Measure Pulmonary Inflammation in Electronic and Combustible Cigarette Users: A Pilot Study.” medRxiv.

405. Wheelis, S. E., et al. (2022). “Effects of Dicationic Imidazolium-Based Ionic Liquid Coatings on Oral Osseointegration of Titanium Implants: A Biocompatibility Study in Multiple Rat Demographics.” Genes 13(4): 642.

406. Willekens, S. M., et al. (2022). “An MR-based brain template and atlas for optical projection tomography and light sheet fluorescence microscopy.” bioRxiv: 2022.2011. 2014.516420.

407. Wiltgen, T., et al. (2022). “18F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio (chemo) therapy.” Radiation Oncology 17(1): 198.

408. Winter, G., et al. (2022). “Preclinical PET and MR Evaluation of 89Zr-and 68Ga-Labeled Nanodiamonds in Mice over Different Time Scales.” Nanomaterials 12(24): 4471.

409. Wu, K.-Y., et al. (2022). “Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology.” Frontiers in aging neuroscience 14.

410. Wuli, W., et al. (2022). “Targeting PSEN1 by lnc-CYP3A43-2/miR-29b-2-5p to reduce β amyloid plaque formation and improve cognition function.” International Journal of Molecular Sciences 23(18): 10554.

411. Wurzer, A., et al. (2022). “Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands (RhPSMAs) for Endoradiotherapy of Prostate Cancer.” Journal of Nuclear Medicine.

412. Xu, J., et al. (2022). “Screening and Preclinical Evaluation of Novel Radiolabeled Anti-Fibroblast Activation Protein-α Recombinant Antibodies.” Cancer Biotherapy & Radiopharmaceuticals.

413. Xu, Y., et al. (2022). “Accelerated HF-rTMS Modifies SERT Availability in the Subgenual Anterior Cingulate Cortex: A Canine [11C] DASB Study on the Serotonergic System.” Journal of clinical medicine 11(6): 1531.

414. Xu, Y., et al. (2022). “Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies.” European Journal of Medicinal Chemistry: 114468.

415. Xue, Y., et al. (2022). “Sustained glymphatic transport and impaired drainage to the nasal cavity observed in multiciliated cell ciliopathies with hydrocephalus.” Fluids and barriers of the CNS 19(1): 1-20.

416. Yahata, N., et al. (2022). “Neural network of superiority illusion predicts the level of dopamine in striatum.” bioRxiv.

417. Yakushev, I., et al. (2022). “Mapping covariance in brain FDG uptake to structural connectivity.” European Journal of Nuclear Medicine and Molecular Imaging 49(4): 1288-1297.

418. Yamabe, S., et al. (2022). “Association of resting left ventricular global longitudinal strain with myocardial perfusion abnormalities evaluated by 13N‐ammonia positron emission tomography in patients with stable angina pectoris and normal left ventricular ejection fraction.” Echocardiography 39(12): 1555-1562.

419. Yamaguchi, T., et al. (2022). “Arterial spin labeling imaging for the detection of cerebral blood flow asymmetry in patients with corticobasal syndrome.” Neuroradiology: 1-9.

420. Yamamoto, M., et al. (2022). “Delivery of aPD-L1 antibody to ip tumors via direct penetration by ip route: Beyond EPR effect.” Journal of Controlled Release 352: 328-337.

421. Yamamoto, Y., et al. (2022). “Radiosynthesis and in Vivo and ex Vivo Evaluation of Isomeric [11C] methoxy Analogs of Nimesulide as Brain Cyclooxygenase-2-Targeted Imaging Agents.” Biological and Pharmaceutical Bulletin 45(1): 94-103.

422. Yamauchi, H., et al. (2022). “Visit-to-Visit Blood PressureVariations and Hemodynamic Deterioration in Atherosclerotic Major Cerebral ArteryDisease.” Journal of Stroke and Cerebrovascular Diseases 31(1): 106206.

423. Yanai, S., et al. (2022). “Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice.” Frontiers in Pharmacology 13: 1031637.

424. Yang, C. Y., et al. (2022). “Enhancing lymphangiogenesis and lymphatic drainage to vascularized lymph nodes with nanofibrillar collagen scaffolds.” Journal of Surgical Oncology 126(7): 1169-1175.

425. Yang, K.-C., et al. (2022). “Role of Dopamine Transporter in the Relationship Between Plasma Cortisol and Cognition.” Psychosomatic Medicine 84(6): 685-694.

426. Yasuno, F., et al. (2022). “Kinetic modeling and non-invasive approach for translocator protein quantification with 11C-DPA-713.” Nuclear Medicine and Biology 108: 76-84.

427. Yasuno, F., et al. (2022). “Estimation of blood-based biomarkers of glial activation related to neuroinflammation.” Brain, Behavior, & Immunity-Health 26: 100549.

428. Yeh, S. H.-H., et al. (2022). “Chelation-Tamoxifen Conjugates for Imaging of Estrogen Receptors.” Cancer Biotherapy & Radiopharmaceuticals 37(1): 30-40.

429. Yeh, S. H.-H., et al. (2022). “Preliminary results on the long-term effects of dextromethorphan on MDMA-mediated serotonergic deficiency and volumetric changes in primates based on 4-[18F]-ADAM PET/MRI.” Frontiers in Neuroscience 16.

430. Yeh, S. H.-H., et al. (2022). “99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable.” Clinical Nuclear Medicine 47(3): 201-208.

431. Ying, W., et al. (2022). “Correlation between 18 F-S16 PET imaging and glucose metabolism pattern in behavioral variant frontotemporal dementia.” Chinese Journal of Contemporary Neurology & Neurosurgery 22(12).

432. Ylä-Herttuala, S., et al. (2022). “Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea.” The Journal of Prevention of Alzheimer’s Disease: 1-8.

433. Yoshimatsu, S., et al. (2022). “Multimodal analyses of a non-human primate model harboring mutant amyloid precursor protein transgenes driven by the human EF1α promoter.” Neuroscience Research 185: 49-61.

434. Young, A. J., et al. (2022). “Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer.” Journal of Nuclear Medicine 63(1): 44-50.

435. Yu, F., et al. (2022). “Spatiotemporal dynamics of brain function during the natural course in a dental pulp injury model.” European Journal of Nuclear Medicine and Molecular Imaging: 1-7.

436. Yu Koh, X., et al. (2022). “Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy.” Scientific Reports 12(1): 22564.

437. Yu, S., et al. (2022). “Circadian rhythm modulates endochondral bone formation via MTR1/AMPKβ1/BMAL1 signaling axis.” Cell Death & Differentiation 29(4): 874-887.

438. Yun, J.-Y. and Y.-K. Kim (2022). “Deficits of Neurotransmitter Systems and Altered Brain Connectivity in Major Depression: A Translational Neuroscience Perspective.” Translational Research Methods for Major Depressive Disorder: 311-324.

439. Zanovello, M., et al. (2022). “Brain Stem Glucose Hypermetabolism in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia and Shortened Survival: An 18F-FDG PET/MRI Study.” Journal of Nuclear Medicine 63(5): 777-784.

440. Zarrouki, F., et al. (2022). “Abnormal Expression of Synaptic and Extrasynaptic GABAA Receptor Subunits in the Dystrophin-Deficient mdx Mouse.” International Journal of Molecular Sciences 23(20): 12617.

441. Zatcepin, A., et al. (2022). “Reduced Acquisition Time [18F] GE-180 PET Scanning Protocol Replaces Gold-Standard Dynamic Acquisition in a Mouse Ischemic Stroke Model.” Frontiers in Medicine 9.

442. Zerweck, L., et al. (2022). “Hemodynamic evaluation of patients with Moyamoya Angiopathy: comparison of resting-state fMRI to breath-hold fMRI and [15O] water PET.” Neuroradiology 64(3): 553-563.

443. Zhang, J., et al. (2022). “18F-FDG PET Combined With MR Spectroscopy Elucidates the Progressive Metabolic Cerebral Alterations After Blast-Induced Mild Traumatic Brain Injury in Rats.” Advanced PET, SPECT, MR and Optical Imaging in Clinical and Pre-Clinical Research of Neuropsychiatric Disorders.

444. Zhang, K., et al. (2022). “Neural correlates of beneficial effects of young plasma treatment in aged mice: PET-SPM analyses and neuro-behavioural/molecular biological studies.” European Journal of Nuclear Medicine and Molecular Imaging 49(5): 1456-1469.

445. Zhang, Q., et al. (2022). “Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia.” Diabetes Research and Clinical Practice 186: 109806.

446. Zhang, S.-s., et al. (2022). “Long-term running exercise improves cognitive function and promotes microglial glucose metabolism and morphological plasticity in the hippocampus of APP/PS1 mice.” Journal of Neuroinflammation 19(1): 1-21.

447. Zhao, Q., et al. (2022). “Enhanced therapeutic efficacy of combining losartan and chemo-immunotherapy for triple negative breast cancer.” Frontiers in Immunology 13: 938439.

448. Zhu, G., et al. (2022). “Design, synthesis, and evaluation of novel O-alkyl ferulamide derivatives as multifunctional ligands for treating Alzheimer’s disease.” Journal of Enzyme Inhibition and Medicinal Chemistry 37(1): 1375-1388.

449. Zhu, X.-X., et al. (2022). “Efficient and automatic synthesis of TSPO PET ligand [18F]-GE-180 and its application in rheumatoid arthritis model.” Applied Radiation and Isotopes 184: 110213.

450. Zia, N., et al. (2022). “Glycol-Chitosan-Based Technetium-99m-Loaded Multifunctional Nanomicelles: Synthesis, Evaluation, and In Vivo Biodistribution.” Nanomaterials 12(13): 2198.

451. Zorick, T., et al. (2022). “The Effects of Citalopram and Thalamic Dopamine D2/3 Receptor Availability on Decision-Making and Loss Aversion in Alcohol Dependence.” Psychiatry Journal 2022.

452. Zuo, Y., et al. (2022). “Comparison of brain nicotine uptake from electronic cigarettes and combustible cigarettes.” Neuropsychopharmacology 47(11): 1939-1944.